NPS has reviewed the newly listed
indacaterol (brand name Onbrez)
for people with chronic obstructive
pulmonary disease (COPD).
Indacaterol is a once-daily long
acting bronchodilator used to treat
the symptoms of COPD, using an
inhaler device called a Breezhaler.
The drug helps reduce shortness
of breath and coughing, but is not
suitable to treat people with
asthma or mixed airways disease.
The review is one of three in-depth
looks at newly listed medicines,
including asenapine for bipolar I
disorder and schizophrenia in NPS’
latest Medicines Update.
NPS has recommended that
anyone who is about to start
indacaterol or asenapine read the
reviews, and then have a discussion
with their GP or pharmacist.
To read the reviews visit -
www.nps.org.au/medicineupdate.The above article was sent to subscribers in Pharmacy Daily's issue from 07 Dec 11 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Dec 11
MEDICATION management platform MedAdvisor Limited (MDR) showed strong financial performance for the quarter concluded on 31 Mar 2024, with operating revenue up 42% to $24.2 million from $17 million for the same period last year.
PHARMACIES in regional areas need a restructure of the 8CPA Community Service Obligation (CSO) to help fund them to support their workforce and deliver services, says the Remote and Isolated Pharmacist Association Australia (RIPAA).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.